Patent number: 12257287
Abstract: Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: HX2QGTFTSDX10SX12YLX15X16X17X18AX20 EFX23X24WLX27X28X29X30X31, wherein the definitions of X2, X10, X12, X15, X16, X17, X18, X20, X23, X24, X27, X28, X29, X30 and X31 are consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.
Type:
Grant
Filed:
November 12, 2019
Date of Patent:
March 25, 2025
Assignee:
Tianjin Institute of Pharmaceutical Research Co., Ltd.
Inventors:
Yingmei Han, Wei Liu, Bingni Liu, Weiling Kong, Naxia Zhao, Guangping Xia, Qian Shang, Xiaohua Kong, Jing Jin, Yuquan Li, Xuyuan Liu